凝血标志物可预测COPD临床事件
基于卑尔根COPD队列3年研究,纳入413例COPD患者和49例对照,部分患者急性加重期复测。稳定期COPD的TAT低于对照,急性加重期TAT、APC-PCI和D-二聚体均升高。稳定期D-二聚体升高预测死亡风险增加,TAT升高与后续急性加重风险增加和首次加重时间缩短相关。
要点
- COPD急性加重期凝血激活标志物TAT、APC-PCI和D-二聚体均较稳定期升高。
- 稳定期D-二聚体升高与死亡风险增加独立相关。
- 稳定期TAT升高预测后续急性加重风险增加及首次加重时间缩短。
核心结论
- COPD急性加重期凝血系统激活增强。
- 凝血标志物是后续COPD急性加重和死亡的潜在预测因子。
研究设计与样本
- 卑尔根COPD队列研究(BCCS),纳入413例COPD患者和49例对照,随访3年。
- 采用酶免疫分析法测定基线及加重期血浆TAT复合物、APC-PCI复合物和D-二聚体。
- 采用负二项回归和Cox回归分析凝血标志物与后续AECOPD及死亡的关系。
主要发现
- 稳定期COPD的TAT为1.03 ng/mL(0.76-1.44),显著低于对照的1.28 ng/mL(1.04-1.49),P=0.002。
- AECOPD期间TAT为2.56 vs 稳定期1.43 ng/mL,APC-PCI为489.3 vs 416.4 ng/mL,D-二聚体为763.5 vs 479.7 ng/mL,P均<0.001。
- 稳定期D-二聚体升高预测死亡风险增加,HR为1.60(1.24-2.05),P<0.001。
- TAT升高与后续急性加重风险增加相关,年发病率比1.19(1.04-1.37)。
- TAT升高与首次急性加重时间缩短相关,HR为1.25(1.10-1.42),P=0.001,均为校正后结果。
临床怎么用
- 稳定期可检测D-二聚体和TAT以辅助识别后续急性加重和死亡高风险患者。
- 急性加重期凝血标志物升高提示凝血激活,可作为病情评估的参考指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Activation of the blood coagulation system is a common observation in inflammatory diseases. The role of coagulation in COPD is underexplored. METHODS: The study included 413 COPD patients and 49 controls from the 3-year Bergen COPD Cohort Study (BCCS). One hundred and forty-eight COPD patients were also examined during AECOPD. The plasma markers of coagulation activation, TAT complex, APC-PCI complex and D-dimer, were measured at baseline and during exacerbations by enzyme immunoassays. Differences in levels of the markers between stable COPD patients and controls, and between stable COPD and AECOPD were examined. The associations between coagulation markers and later AECOPD and mortality were examined by negative binomial and Cox regression analyses. RESULTS: TAT was significantly lower in stable COPD (1.03 ng/mL (0.76-1.44)) than in controls (1.28 (1.04-1.49), P = 0.002). During AECOPD, all markers were higher than in the stable state: TAT 2.56 versus 1.43 ng/mL, APC-PCI 489.3 versus 416.4 ng/mL and D-dimer 763.5 versus 479.7 ng/mL (P < 0.001 for all). Higher D-dimer in stable COPD predicted a higher mortality (HR: 1.60 (1.24-2.05), P < 0.001). Higher TAT was associated with both an increased risk of later exacerbations, with a yearly incidence rate ratio of 1.19 (1.04-1.37), and a faster time to the first exacerbation (HR: 1.25 (1.10-1.42), P = 0.001, all after adjustment). CONCLUSION: Activation of the coagulation system is increased during COPD exacerbations. Coagulation markers are potential predictors of later COPD exacerbations and mortality.
引用
- Husebø GR, Gabazza EC, D'Alessandro Gabazza C, et al. Coagulation markers as predictors for clinical events in COPD. Respirology. 2020. PMID: 33164314. doi:10.1111/resp.13971
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。